Drug intelligence / Profile preview

MK

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK is a novel small molecule compound developed by Merck & Co., Inc. for the treatment of Type 2 diabetes (T2D). It has been shown to stimulate glucagon secretion and inhibit the effect of glucagon on glucose production, thereby influencing glucose, glucagon, and insulin profiles in the body. The drug has undergone Phase I and Phase IIa clinical studies.

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on MK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK.

Explore the full profile